Cargando…

Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum

Multidrug resistant Plasmodium falciparum in Southeast Asia endangers regional malaria elimination and threatens to spread to other malaria endemic areas. Understanding mechanisms of piperaquine (PPQ) resistance is crucial for tracking its emergence and spread, and to develop effective strategies fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bopp, Selina, Magistrado, Pamela, Wong, Wesley, Schaffner, Stephen F., Mukherjee, Angana, Lim, Pharath, Dhorda, Mehul, Amaratunga, Chanaki, Woodrow, Charles J., Ashley, Elizabeth A., White, Nicholas J., Dondorp, Arjen M., Fairhurst, Rick M., Ariey, Frederic, Menard, Didier, Wirth, Dyann F., Volkman, Sarah K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931971/ https://www.ncbi.nlm.nih.gov/pubmed/29720620 http://dx.doi.org/10.1038/s41467-018-04104-z

Ejemplares similares

Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia
por: Mukherjee, Angana, et al.
Publicado: (2017)

Artemisinin and multidrug-resistant Plasmodium falciparum – a threat for malaria control and elimination
por: Dhorda, Mehul, et al.
Publicado: (2021)

Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum
por: Ansbro, Megan R., et al.
Publicado: (2020)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine
por: Loesbanluechai, Duangkamon, et al.
Publicado: (2018)

A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance
por: Kane, John, et al.
Publicado: (2023)

Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations
por: Tindana, Paulina, et al.
Publicado: (2021)

Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
por: Nguyen, Tran Dang, et al.
Publicado: (2023)

African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker
por: Leroy, Didier, et al.
Publicado: (2019)

A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria
por: Mokuolu, Olugbenga Ayodeji, et al.
Publicado: (2023)

Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
por: Tindana, Paulina, et al.
Publicado: (2022)

Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization
por: Boonyalai, Nonlawat, et al.
Publicado: (2020)

α(+)Thalassemia Antagonizes the Malaria-protective Effects of Sickle-Cell Trait
por: Amaratunga, Chanaki, et al.
Publicado: (2014)

Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies
por: Tripura, Rupam, et al.
Publicado: (2016)

Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study
por: de Haan, Freek, et al.
Publicado: (2022)

Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X
por: Li, Fengwu, et al.
Publicado: (2016)

A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages
por: Tripura, Rupam, et al.
Publicado: (2018)

Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine
por: Ross, Leila S., et al.
Publicado: (2018)

Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
por: O’Flaherty, Katherine, et al.
Publicado: (2019)

The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
por: Guissou, Rosemonde M., et al.
Publicado: (2023)

Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial
por: Awab, Ghulam Rahim, et al.
Publicado: (2010)

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
por: van der Pluijm, Rob W, et al.
Publicado: (2019)

Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
por: Foguim Tsombeng, Francis, et al.
Publicado: (2019)

To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
por: de Haan, Freek, et al.
Publicado: (2021)

Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
por: Tindana, Paulina, et al.
Publicado: (2021)

Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial
por: Hamaluba, Mainga, et al.
Publicado: (2021)

Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples
por: Venkatesan, Meera, et al.
Publicado: (2012)

Essentiality of Plasmodium falciparum plasmepsin V
por: Boonyalai, Nonlawat, et al.
Publicado: (2018)

Plasmepsin-like Aspartyl Proteases in Babesia
por: Šnebergerová, Pavla, et al.
Publicado: (2021)

Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study
por: Amato, Roberto, et al.
Publicado: (2018)

Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
por: Cutts, Julia C, et al.
Publicado: (2022)

Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
por: Duru, Valentine, et al.
Publicado: (2015)

High Antimalarial Efficacy of Dihydroartemisinin–Piperaquine on the China–Myanmar Border: The Calm before the Storm
por: Fairhurst, Rick M.
Publicado: (2015)

Establishing research priorities for malaria elimination in the context of the emergency response to artemisinin resistance framework-the Cambodian approach
por: Canavati, Sara E., et al.
Publicado: (2016)

Complexity of Infection and Genetic Diversity in Cambodian Plasmodium vivax
por: Friedrich, Lindsey R., et al.
Publicado: (2016)

Plasmepsin V, a Secret Weapon Against Malaria
por: Sedwick, Caitlin
Publicado: (2014)

Plasmodium falciparum Plasmepsin 2 Duplications, West Africa
por: Inoue, Juliana, et al.
Publicado: (2018)

Synthesis of Plasmepsin II Inhibitors – Potential Antimalarial Agents
por: Mueller, Reto, et al.
Publicado: (2003)

Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
por: O’Flaherty, Katherine, et al.
Publicado: (2022)

Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria
por: Intharabut, Benjamas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k1ds014g7n94lkqpt9530pjv5u